Brain-computer interface (BCI) has reached a milestone in neural rehabilitation. Recently, a multicenter clinical trial published in *Nature Medicine* demonstrated that a non-invasive BCI-driven exoskeleton device improved upper limb Fugl-Meyer scores by an average of 12.3 points in chronic stroke patients after 12 weeks of training, 45% higher than the conventional rehabilitation group. The device captures motor cortex signals via scalp electrodes, decodes intentions in real-time, and triggers robotic arms to assist with movements such as grasping and lifting, increasing patients' effective daily training volume to 2.5 times that of traditional therapy. This technology has received FDA Breakthrough Device Designation and is expected to enter routine clinical use by 2025.
In Shanghai, Huashan Hospital Affiliated to Fudan University has introduced a similar BCI system for localized adaptation. After optimizing the neural decoding model for Chinese-speaking populations, target recognition accuracy has reached 92%. Meanwhile, Meijiakang is actively collaborating with rehabilitation departments of multiple top-tier hospitals to promote the evaluation and implementation of BCI rehabilitation protocols, and has updated its cost estimator tool to include relevant treatment items.
Background and Significance
Globally, over 12 million new stroke patients are reported annually, with approximately 60% experiencing upper limb dysfunction. Traditional rehabilitation relies on one-on-one guidance from physical therapists, limiting intensity and frequency, and showing minimal efficacy for chronic patients beyond six months post-onset. BCI technology breaks the old limitation of the "neural remodeling window period" by activating brain plasticity through high-frequency, closed-loop motor intention-feedback cycles, enabling functional improvement even in cases with disease duration exceeding one year. In this trial, the average disease duration of enrolled patients was 2.3 years, and the efficacy data directly challenges the clinical notion of "no hope for recovery," opening a new interventional dimension in neural repair.
Significance for International Patients
For overseas patients, BCI rehabilitation devices represent a more definitive treatment option. Currently, this technology is concentrated in a few countries such as the United States and Germany, with single-course costs ranging from $50,000 to $80,000 and waiting periods exceeding six months. Although China started later in BCI clinical research, it has achieved cost control in signal acquisition algorithms and lightweight hardware, leveraging its vast case database and engineering talent pool. For example, at a partner hospital in Shanghai, a 10-week intensive BCI rehabilitation program is priced at approximately 40% of comparable U.S. offerings, including language adaptation and remote follow-up. Additionally, many regions in China have opened medical tourism visas to support continuous treatment stays for international patients, providing a practical pathway for those seeking cost-effective neural rehabilitation solutions.
How Meijiakang Helps
As a cross-border medical platform, Meijiakang specializes in connecting international patients with top-tier neural rehabilitation resources in China. We offer three core services: First, precise hospital and expert matching, screening institutions with BCI device qualifications and extensive clinical experience based on patients' imaging data and functional impairment assessments; Second, customized cost plans, integrating treatment, accommodation, translation, and rehabilitation aid expenses to avoid hidden charges; Third, comprehensive medical coordination, including remote initial consultations, visa assistance, expedited hospital admission, and post-discharge rehabilitation guidance. To obtain the latest BCI rehabilitation program list and quotes, feel free to contact us.
Related reading: Overview of Partner Hospitals in Shanghai